Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
P
PRME
vs
S&P 500
S&P 500
Over the past 12 months, PRME has underperformed S&P 500, delivering a return of -50% compared to S&P 500's +15% growth.
Stocks Performance
PRME vs S&P 500
Performance Gap
PRME vs S&P 500
Performance By Year
PRME vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Prime Medicine Inc
Glance View
Prime Medicine is a biotechnology company that develops gene-editing medicines based on a technique called prime editing. Its goal is to rewrite faulty DNA inside human cells so doctors can treat the root cause of certain diseases rather than only managing symptoms. The company is still focused on research and drug development, not on selling a broad range of commercial products. The company’s main customers are not traditional retail buyers. Its work is aimed at patients, hospitals, and doctors through future approved therapies, and at larger pharmaceutical partners that may license or collaborate on the technology. Prime Medicine makes money mainly through research collaborations, licensing arrangements, and, if its programs succeed, eventual sales of approved treatments. What makes Prime Medicine different is its place in the gene-editing value chain. It is building medicines around prime editing, a newer and more precise approach than older gene-editing tools because it is designed to make targeted DNA changes without cutting both strands of DNA in the same way. That gives the company a shot at treating genetic diseases where a one-time correction could be more useful than long-term drug treatment.